SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH M impact

Dogwood Therapeutics Announces Third-Quarter 2026 Results

Dogwood Therapeutics reported third-quarter 2026 financial results and said it completed the Halneuron Phase 2b trial in chemotherapy-induced neuropathy. Top-line results are to be released later; timing was not provided.

DWTX
SquawkNews Desk 2 updates Updated Nov 05, 2026, 01:32 PM UTC

Story updates

01:32:18 PM UTC
SquawkNews
Dogwood Therapeutics 3Q Loss/Shr 14c >DWTX
01:32:18 PM UTC
SquawkNews
Dogwood Therapeutics 3Q Rev $100,000 >DWTX

Related stories

BGC Group Q3 Revenue Rises 13%, Adjusted EPS Up 17% M impact | EQUITY | Nov 05, 2026, 01:37 PM UTC Dogwood Therapeutics Reports Third-Quarter 2026 Financial Results The company says it completed its Phase 2b trial of Halneuron for chemotherapy-induced neuropathy; top-line results are expected in November 2026. Its Phase 2b long-term extension M impact | EQUITY | Nov 05, 2026, 01:37 PM UTC Ondas Agrees to Acquire Stemme, Targets 10 ULTRA Aircraft Monthly by 2028 Ondas agreed to acquire 100% of Stemme GmbH in an all-cash transaction, subject to customary conditions and regulatory approvals. Closing is expected in Q1 2027; Ondas targets ULTR M impact | EQUITY | Nov 05, 2026, 01:37 PM UTC MDU Resources Q3 Earnings Snapshot M impact | EQUITY | Nov 05, 2026, 01:36 PM UTC Liberty Media Posts Q3 Revenue of $1.23B Liberty Media reported Q3 revenue of $1.23 billion, versus a FactSet estimate of $1.24 billion. M impact | EQUITY | Nov 05, 2026, 01:35 PM UTC Marex Q3 Adjusted Earnings and Revenue Rise Marex reported Q3 adjusted earnings of $1. M impact | EQUITY | Nov 05, 2026, 01:35 PM UTC